🇺🇸 FDA
Patent

US 11944617

Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4

granted A61KA61K31/337A61K31/4725

Quick answer

US patent 11944617 (Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4) held by Corcept Therapeutics Incorporated expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Corcept Therapeutics Incorporated
Grant date
Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/337, A61K31/4725, A61K31/4745, A61P